Alzheimer's disease: Targeting the cholinergic system

Current Neuropharmacology

Volumn 14, Issue 1, 2016, Pages 101-115

  Ferreira Vieira, Talita H ^a   Guimaraes, Isabella M ^a   Silva, Flavia R ^a   Ribeiro, Fabiola M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Acetylcholine; AChE; Alzheimer s disease; ChAT; CHT1; VAChT

Indexed keywords

ACETYL COENZYME A; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AF267B; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CHOLINE ACETYLTRANSFERASE; CHOLINE TRANSPORTER; CHOLINERGIC RECEPTOR; DONEPEZIL; GALANTAMINE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NICOTINIC RECEPTOR; RIVASTIGMINE; SC 72788; SCH 57790; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER; XANOMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ATTENTION DEFICIT DISORDER; CHOLINE UPTAKE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DEMENTIA; EXOCYTOSIS; HUMAN; MEMORY DISORDER; NEUROFIBRILLARY TANGLE; PASSIVE IMMUNIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; PROCEDURES; TRENDS;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CHOLINERGIC AGENTS; CHOLINERGIC NEURONS; CHOLINESTERASE INHIBITORS; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, CHOLINERGIC;

EID: 84958527611     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x13666150716165726     Document Type: Article

References (273)

1. [1][1] Loewi, O. Uber humerole ubertragbarkeit der herznervenwirkung. I Mitteilung Pflugers Arch., 1921, 189, 239-242.http://dx.doi.org/10.1007/BF01738910
2. [2][2] Armstrong, D.M.; Saper, C.B.; Levey, A.I.; Wainer, B. h.; Terry, R.D. Distribution of cholinergic neurons in rat brain: demonstrated by the immunocytochemical localization of choline acetyltransferase. J. Comp. Neurol., 1983, 216, 53-68.http://dx.doi.org/10.1002/cne.902160106
3. [3][3] Woolf, N.J.; Butcher, L.L. Cholinergic systems mediate action from movement to higher consciousness. Behav. Brain Res., 2011, 221, 488-498.http://dx.doi.org/10.1016/j.bbr.2009.12.046
4. [4][4] Houser, C.R.; Crawford, G.D.; Barber, R.P.; Salvaterra, P.M.; Vaughn, J.E. Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res., 1983, 266, 97-119.http://dx.doi.org/10.1016/0006-8993(83)91312-4
5. [5][5] Kimura, H.; McGeer, P.L.; Peng, J. h.; McGeer, E.G. The central cholinergic system studied by choline acetyltransferase immunohistochemistry in the cat. J. Comp. Neurol., 1981, 200, 151-201.http://dx.doi.org/10.1002/cne.902000202
6. [6][6] Lucas-Meunier, E.; Fossier, P.; Baux, G.; Amar, M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch., 2003, 446, 17-29.http://dx.doi.org/10.1007/s00424-002-0999-2
7. [7][7] Woolf, N.J. Cholinergic systems in mammalian brain and spinal cord. Prog. Neurobiol., 1991, 37, 475-524.http://dx.doi.org/10.1016/0301-0082(91)90006-M
8. [8][8] Bucci, D.J.; Holland, P.C.; Gallagher, M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J. Neurosci., 1998, 18, 8038-8046.
9. [9][9] Voytko, M.L.; Olton, D.S.; Richardson, R.T.; Gorman, L.K.; Tobin, J.R.; Price, D.L. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci., 1994, 14, 167-186.
10. [10][10] Pepeu, G.; Giovannini, M.G.; Bracco, L. Effect of cholinesterase inhibitors on attention. Chem. Biol. Interact., 2013, 203, 361-364.http://dx.doi.org/10.1016/j.cbi.2012.09.016
11. [11][11] Bracco, L.; Bessi, V.; Padiglioni, S.; Marini, S.; Pepeu, G. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients. J. Alzheimers Dis., 2014, 40, 737-742.
12. [12][12] Fine, A.; Hoyle, C.; Maclean, C.J.; Levatte, T.L.; Baker, H.F.; Ridley, R.M. Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys. Neuroscience, 1997, 81, 331-343.http://dx.doi.org/10.1016/S0306-4522(97)00208-X
13. [13][13] Miranda, M.I.; Bermudez-Rattoni, F. Reversible inactivation of the nucleus basalis magnocellularis induces disruption of cortical acetylcholine release and acquisition, but not retrieval, of aversive memories. Proc. Natl. Acad. Sci. U.S.A, 1999, 96, 6478-6482.http://dx.doi.org/10.1073/pnas.96.11.6478
14. [14][14] Dunnett, S.B.; Everitt, B.J.; Robbins, T.W. The basal forebraincortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci., 1991, 14, 494-501.http://dx.doi.org/10.1016/0166-2236(91)90061-X
15. [15][15] Hasselmo, M.E.; Anderson, B.P.; Bower, J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol., 1992, 67, 1230-1246.
16. [16][16] Sarter, M.; Bruno, J.P. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res. Brain Res. Rev., 1997, 23, 28-46.http://dx.doi.org/10.1016/S0165-0173(96)00009-4
17. [17][17] Blokland, A.; Honig, W.; Raaijmakers, W.G. Effects of intrahippocampal scopolamine injections in a repeated spatial acquisition task in the rat. Psychopharmacology (Berl), 1992, 109, 373-376.http://dx.doi.org/10.1007/BF02245886
18. [18][18] Winters, B.D.; Bussey, T.J. Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat. Eur. J. Neurosci., 2005, 21, 2263-2270.http://dx.doi.org/10.1111/j.1460-9568.2005.04055.x
19. [19][19] Power, A.E.; Vazdarjanova, A.; McGaugh, J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem., 2003, 80, 178-193.http://dx.doi.org/10.1016/S1074-7427(03)00086-8
20. [20][20] Boccia, M.M.; Acosta, G.B.; Blake, M.G.; Baratti, C.M. Memory consolidation and reconsolidation of an inhibitory avoidance response in mice: effects of i.c.v. injections of hemicholinium-3. Neuroscience, 2004, 124, 735-741.http://dx.doi.org/10.1016/j.neuroscience.2004.01.001
21. [21][21] Boccia, M.M.; Blake, M.G.; Baratti, C.M.; McGaugh, J.L. Involvement of the basolateral amygdala in muscarinic cholinergic modulation of extinction memory consolidation. Neurobiol. Learn. Mem., 2009, 91, 93-97.http://dx.doi.org/10.1016/j.nlm.2008.07.012
22. [22][22] Boccia, M.M.; Blake, M.G.; Acosta, G.B.; Baratti, C.M. Atropine, an anticholinergic drug, impairs memory retrieval of a high consolidated avoidance response in mice. Neurosci. Lett., 2003, 345, 97-100.http://dx.doi.org/10.1016/S0304-3940(03)00493-2
23. [23][23] Whitehouse, P.J.; Price, D.L.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol., 1981, 10, 122-126.http://dx.doi.org/10.1002/ana.410100203
24. [24][24] Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215, 1237-1239.http://dx.doi.org/10.1126/science.7058341
25. [25][25] Janowsky DS, R.S. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorder and stress. Drug Dev. Res., 1984, 4, 17.http://dx.doi.org/10.1002/ddr.430040202
26. [26][26] Newman, M.B.; Nazian, S.J.; Sanberg, P.R.; Diamond, D.M.; Shytle, R.D. Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25, 609-620.http://dx.doi.org/10.1016/S0278-5846(00)00178-0
27. [27][27] Matta, S.G.; Fu, Y.; Valentine, J.D.; Sharp, B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology, 1998, 23, 103-113.http://dx.doi.org/10.1016/S0306-4530(97)00079-6
28. [28] Jasper, H. h.; Tessier, J. Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep. Science, 1971, 172, 601-602.http://dx.doi.org/10.1126/science.172.3983.601
29. [29][29] Baghdoyan, H.A.; Rodrigo-Angulo, M.L.; McCarley, R.W.; Hobson, J.A. Site-specific enhancement and suppression of desynchronized sleep signs following cholinergic stimulation of three brainstem regions. Brain Res., 1984, 306, 39-52.http://dx.doi.org/10.1016/0006-8993(84)90354-8
30. [30][30] Donoghue, J.P.; Carroll, K.L. Cholinergic modulation of sensory responses in rat primary somatic sensory cortex. Brain Res., 1987, 408, 367-371.http://dx.doi.org/10.1016/0006-8993(87)90407-0
31. [31][31] Metherate, R.; Cox, C.L.; Ashe, J. h. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine. J. Neurosci., 1992, 12, 4701-4711.
32. [32][32] Rasmusson, D.D.; Dykes, R.W. Long-term enhancement of evoked potentials in cat somatosensory cortex produced by co-activation of the basal forebrain and cutaneous receptors. Exp. Brain Res., 1988, 70, 276-286.http://dx.doi.org/10.1007/BF00248353
33. [33] Sillito, A.M.; Kemp, J.A. Cholinergic modulation of the functional organization of the cat visual cortex. Brain Res., 1983, 289, 143-155.http://dx.doi.org/10.1016/0006-8993(83)90015-X
34. [34][34] Paez-Gonzalez, P.; Asrican, B.; Rodriguez, E.; Kuo, C.T. Identification of distinct ChAT(+) neurons and activity-dependent control of postnatal SVZ neurogenesis. Nat. Neurosci., 2014, 17, 934-942.http://dx.doi.org/10.1038/nn.3734
35. [35] Potter, L.T. Synthesis, storage and release of [14C]acetylcholine in isolated rat diaphragm muscles. J. Physiol., 1970, 206, 145-166.http://dx.doi.org/10.1113/jphysiol.1970.sp009003
36. [36][36] Nachmansohn, D.; Machado, A.L. The formation of acetylcholine. A new enzyme choline acetylase. J. Neurophysiol., 1943, 6, 397-403.
37. [37][37] Hoffbauer, F.W.; Zaki, F.G. Choline deficiency in baboon and rat compared. Arch.Pathol., 1965, 79, 364-369.
38. [38][38] Zeisel, S. h.; Da Costa, K.A.; Franklin, P.D.; Alexander, E.A.; Lamont, J.T.; Sheard, N.F.; Beiser, A. Choline, an essential nutrient for humans. FASEB J, 1991, 5, 2093-2098.
39. [39][39] Benishin, C.G.; Carroll, P.T. Acetylation of choline and homocholine by membrane-bound choline-O-acetyltransferase in mouse forebrain nerve endings. J. Neurochem., 1981, 36, 732-740.http://dx.doi.org/10.1111/j.1471-4159.1981.tb01649.x
40. [40][40] Rylett, R.J. Synaptosomal “membrane-bound” choline acetyltrans ferase is most sensitive to inhibition by choline mustard. J. Neurochem., 1989, 52, 869-875.http://dx.doi.org/10.1111/j.1471-4159.1989.tb02535.x
41. [41][41] Misawa, H.; Matsuura, J.; Oda, Y.; Takahashi, R.; Deguchi, T. Human choline acetyltransferase mRNAs with different 5'-region produce a 69-kDa major translation product. Brain Res. Mol. Brain Res., 1997, 44, 323-333.http://dx.doi.org/10.1016/S0169-328X(96)00231-8
42. [42][42] Oda, Y.; Nakanishi, I.; Deguchi, T. A complementary DNA for human choline acetyltransferase induces two forms of enzyme with different molecular weights in cultured cells. Brain Res. Mol. Brain Res., 1992, 16, 287-294.http://dx.doi.org/10.1016/0169-328X(92)90237-6
43. [43][43] Resendes, M.C.; Dobransky, T.; Ferguson, S.S.; Rylett, R.J. Nuclear localization of the 82-kDa form of human choline acetyltransferase. J. Biol. Chem., 1999, 274, 19417-19421.http://dx.doi.org/10.1074/jbc.274.27.19417
44. [44][44] Gill, S.K.; Bhattacharya, M.; Ferguson, S.S.; Rylett, R.J. Identification of a novel nuclear localization signal common to 69- and 82-kDa human choline acetyltransferase. J. Biol. Chem., 2003, 278, 20217-20224.http://dx.doi.org/10.1074/jbc.M213153200
45. [45][45] Gill, S.K.; Ishak, M.; Dobransky, T., Haroutunian, V.; Davis, K.L.; Rylett, R.J. 82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease. Neurobiol. Aging, 2007, 28, 1028-1040.http://dx.doi.org/10.1016/j.neurobiolaging.2006.05.011
46. [46][46] Bruce, G.; Hersh, L.B. The phosphorylation of choline acetyltransferase. Neurochem. Res., 1989, 14, 613-620.http://dx.doi.org/10.1007/BF00964869
47. [47][47] Schmidt, B.M.; Rylett, R.J. Phosphorylation of rat brain choline acetyltransferase and its relationship to enzyme activity. J. Neurochem., 1993, 61, 1774-1781.http://dx.doi.org/10.1111/j.1471-4159.1993.tb09815.x
48. [48][48] Dobransky, T.; Davis, W.L.; Xiao, G. h.; Rylett, R.J. Expression, purification and characterization of recombinant human choline acetyltransferase: phosphorylation of the enzyme regulates catalytic activity. Biochem. J., 2000, 349, 141-151.http://dx.doi.org/10.1042/bj3490141
49. [49][49] Collier, B.; Katz, H.S. Acetylcholine synthesis from recaptured choline by a sympathetic ganglion. J. Physiol., 1974, 238, 639-655.http://dx.doi.org/10.1113/jphysiol.1974.sp010548
50. [50][50] Simon, J.R.; Kuhar, M.G. Impulse-flow regulation of high affinity choline uptake in brain cholinergic nerve terminals. Nature, 1975, 255, 162-163.http://dx.doi.org/10.1038/255162a0
51. [51][51] Roghani, A.; Feldman, J.; Kohan, S.A.; Shirzadi, A.; Gundersen, C.B.; Brecha, N.; Edwards, R. h. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc. Natl. Acad. Sci. U.S.A, 1994, 91, 10620-10624.http://dx.doi.org/10.1073/pnas.91.22.10620
52. [52][52] Bejanin, S.; Cervini, R.; Mallet, J.; Berrard, S. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem., 1994, 269, 21944-21947.
53. [53][53] Erickson, J.D.; Varoqui, H.; Schafer, M.K.; Modi, W.; Diebler, M.F.; Weihe, E.; Rand, J.; Eiden, L.E.; Bonner, T.I.; Usdin, T.B. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem., 1994, 269, 21929-21932.
54. [54][54] Alfonso, A.; Grundahl, K.; McManus, J.R.; Asbury, J.M.; Rand, J.B. Alternative splicing leads to two cholinergic proteins in Caenorhabditis elegans. J. Mol. Biol., 1994, 241, 627-630.http://dx.doi.org/10.1006/jmbi.1994.1538
55. [55][55] Eiden, L.E. The cholinergic gene locus. J. Neurochem., 1998, 70, 2227-2240.http://dx.doi.org/10.1046/j.1471-4159.1998.70062227.x
56. [56][56] Kitamoto, T.; Wang, W.; Salvaterra, P.M. Structure and organization of the Drosophila cholinergic locus. J. Biol. Chem., 1998, 273, 2706-2713.http://dx.doi.org/10.1074/jbc.273.5.2706
57. [57] Misawa, H.; Ishii, K.; Deguchi, T. Gene expression of mouse choline acetyltransferase. Alternative splicing and identification of a highly active promoter region. J. Biol. Chem., 1992, 267, 20392-20399.
58. [58][58] Cervini, R.; Houhou, L.; Pradat, P.F.; Bejanin, S.; Mallet, J.; Berrard, S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem., 1995, 270, 24654-24657.http://dx.doi.org/10.1074/jbc.270.42.24654
59. [59][59] Usdin, T.B.; Eiden, L.E.; Bonner, T.I.; Erickson, J.D. Molecular biology of the vesicular ACh transporter. Trends Neurosci., 1995, 18, 218-224.http://dx.doi.org/10.1016/0166-2236(95)93906-E
60. [60][60] Holler, T.; Berse, B.; Cermak, J.M.; Diebler, M.F.; Blusztajn, J.K. Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Neurosci. Lett., 1996, 212, 107-110.http://dx.doi.org/10.1016/0304-3940(96)12808-1
61. [61][61] Alfonso, A.; Grundahl, K.; Duerr, J.S.; Han, H.P.; Rand, J.B. The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science, 1993, 261, 617-619.http://dx.doi.org/10.1126/science.8342028
62. [62][62] Varoqui, H.; Diebler, M.F.; Meunier, F.M.; Rand, J.B.; Usdin, T.B.; Bonner, T.I.; Eiden, L.E.; Erickson, J.D. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans. FEBS Lett., 1994, 342, 97-102.http://dx.doi.org/10.1016/0014-5793(94)80592-X
63. [63][63] Whittaker, V.P. Cholinergic synaptic vesicles from the electromotor nerve terminals of Torpedo. Composition and life cycle. Ann. N.Y. Acad. Sci., 1987, 493, 77-91.http://dx.doi.org/10.1111/j.1749-6632.1987.tb27185.x
64. [64][64] Rebois, R.V.; Reynolds, E.E.; Toll, L.; Howard, B.D. Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry, 1980, 19, 1240-1248.http://dx.doi.org/10.1021/bi00547a031
65. [65][65] Anderson, D.C.; King, S.C.; Parsons, S.M. Pharmacological characterization of the acetylcholine transport system in purified Torpedo electric organ synaptic vesicles. Mol. Pharmacol., 1983, 24, 48-54.
66. [66] Bahr, B.A.; Parsons, S.M. Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4- phenyl [3, 4-3H]-piperidino) cyclohexanol. Proc. Natl. Acad. Sci. U.S.A, 1986, 83, 2267-2270.http://dx.doi.org/10.1073/pnas.83.7.2267
67. [67][67] Varoqui, H.; Erickson, J.D. The cytoplasmic tail of the vesicular acetylcholine transporter contains a synaptic vesicle targeting signal. J. Biol. Chem., 1998, 273, 9094-9098.http://dx.doi.org/10.1074/jbc.273.15.9094
68. [68][68] Krantz, D.E.; Waites, C.; Oorschot, V.; Liu, Y.; Wilson, R.I.; Tan, P.K.; Klumperman, J.; Edwards, R. h. A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles. J. Cell Biol., 2000, 149, 379-396.http://dx.doi.org/10.1083/jcb.149.2.379
69. [69][69] Santos, M.S.; Barbosa, J., Jr.; Veloso, G.S.; Ribeiro, F.; Kushmerick, C.; Gomez, M.V.; Ferguson, S.S.; Prado, V.F.; Prado, M.A. Trafficking of green fluorescent protein tagged-vesicular acetylcholine transporter to varicosities in a cholinergic cell line. J. Neurochem., 2001, 78, 1104-1113.http://dx.doi.org/10.1046/j.1471-4159.2001.00494.x
70. [70][70] Ferreira, L.T.; Santos, M.S.; Kolmakova, N.G.; Koenen, J.; Barbosa, J.J.; Gomez, M.V.; Guatimosim, C.; Zhang, X.; Parsons, S.M.; Prado, V.F.; Prado, M.A. Structural requirements for steadystate localization of the vesicular acetylcholine transporter. J. Neurochem., 2005, 94, 957-969.http://dx.doi.org/10.1111/j.1471-4159.2005.03244.x
71. [71][71] Barbosa, J., Jr.; Clarizia, A.D.; Gomez, M.V.; Romano-Silva, M.A.; Prado, V.F.; Prado, M.A. Effect of protein kinase C activation on the release of [3H]acetylcholine in the presence of vesamicol. J. Neurochem., 1997, 69, 2608-2611.http://dx.doi.org/10.1046/j.1471-4159.1997.69062608.x
72. [72][72] Cho, G.W.; Kim, M. h.; Chai, Y.G.; Gilmor, M.L.; Levey, A.I.; Hersh, L.B. Phosphorylation of the rat vesicular acetylcholine transporter. J. Biol. Chem., 2000, 275, 19942-19948.http://dx.doi.org/10.1074/jbc.M902174199
73. [73][73] Prado, V.F.; Martins-Silva, C.; de Castro, B.M.; Lima, R.F.; Barros, D.M.; Amaral, E.; Ramsey, A.J.; Sotnikova, T.D.; Ramirez, M.R.; Kim, H.G.; Rossato, J.I.; Koenen, J.; Quan, H.; Cota, V.R.; Moraes, M.F.; Gomez, M.V.; Guatimosim, C.; Wetsel, W.C.; Kushmerick, C.; Pereira, G.S.; Gainetdinov, R.R.; Izquierdo, I.; Caron, M.G.; Prado, M.A. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron, 2006, 51, 601-612.http://dx.doi.org/10.1016/j.neuron.2006.08.005
74. [74][74] Augustinsson, K.B.; Nachmansohn, D. Distinction between Acetylcholine-Esterase and Other Choline Ester-splitting Enzymes. Science, 1949, 110, 98-99.http://dx.doi.org/10.1126/science.110.2847.98
75. [75][75] Hall, Z.W. Multiple forms of acetylcholinesterase and their distribution in endplate and non-endplate regions of rat diaphragm muscle. J. Neurobiol., 1973, 4, 343-361.http://dx.doi.org/10.1002/neu.480040404
76. [76][76] McMahan, U.J.; Sanes, J.R.; Marshall, L.M. Cholinesterase is associated with the basal lamina at the neuromuscular junction. Nature, 1978, 271, 172-174.http://dx.doi.org/10.1038/271172a0
77. [77][77] Potter, P.E.; Hadjiconstantinou, M.; Meek, J.L.; Neff, N. h. Measurement of acetylcholine turnover rate in brain: an adjunct to a simple HPLC method for choline and acetylcholine. J. Neurochem., 1984, 43, 288-290.http://dx.doi.org/10.1111/j.1471-4159.1984.tb06712.x
78. [78][78] Soreq, H.; Seidman, S. Acetylcholinesterase--new roles for an old actor. Nat. Rev. Neurosci., 2001, 2, 294-302.http://dx.doi.org/10.1038/35067589
79. [79][79] Schumacher, M.; Maulet, Y.; Camp, S.; Taylor, P. Multiple messenger RNA species give rise to the structural diversity in acetylcholinesterase. J. Biol. Chem., 1988, 263, 18979-18987.
80. [80][80] Maulet, Y.; Camp, S.; Gibney, G.; Rachinsky, T.L.; Ekstrom, T.J.; Taylor, P. Single gene encodes glycophospholipid-anchored and asymmetric acetylcholinesterase forms: alternative coding exons contain inverted repeat sequences. Neuron, 1990, 4, 289-301.http://dx.doi.org/10.1016/0896-6273(90)90103-M
81. [81][81] Seidman, S.; Sternfeld, M.; Aziz-Aloya, R.; Timberg, R.; Kaufer- Nachum, D.; Soreq, H. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3'-terminal exons. Mol. Cell Biol., 1995, 15, 2993-3002.http://dx.doi.org/10.1128/MCB.15.6.2993
82. [82][82] Roberts, W.L.; Kim, B. h.; Rosenberry, T.L. Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc. Natl. Acad. Sci. U.S.A, 1987, 84, 7817-7821.http://dx.doi.org/10.1073/pnas.84.22.7817
83. [83][83] Li, Y.; Camp, S.; Rachinsky, T.L.; Getman, D.; Taylor, P. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J. Biol. Chem., 1991, 266, 23083-23090.
84. [84][84] Costa, L.G. Current issues in organophosphate toxicology. Clin. Chim. Acta, 2006, 366, 1-13.http://dx.doi.org/10.1016/j.cca.2005.10.008
85. [85][85] Wilson, I.B. Molecular complementarity and antidotes for alkylphosphate poisoning. Fed. Proc., 1959, 18, 752-758.
86. [86][86] de Schaepdryver, A.; Marion, C. Succinylcholine in anesthesiology. Acta Anaesthesiol., 1952, 3, 105-109.
87. [87][87] Castillo, J.C.; De Beer, E.J. The neuromuscular blocking action of succinylcholine (diacetylcholine). J. Pharmacol. Exp. Ther., 1950, 99, 458-464.
88. [88][88] Burns, A.; Russell, E.; Page, S. New drugs for Alzheimer's disease. Br. J. Psychiatry, 1999, 174, 476-479.http://dx.doi.org/10.1192/bjp.174.6.476
89. [89][89] Davis, K.L.; Mohs, R.C.; Tinklenberg, J.R.; Physostigmine: improvement of long-term memory processes in normal humans. Science, 1978, 201, 272-274.http://dx.doi.org/10.1126/science.351807
90. [90][90] Birks, R.I.; MacIntosh, F.C., Birks, R.I., MacIntosh, F.C., 1961. Acetylcholine metabolism of a sympathetic ganglion. Can. J. Biochem. Physiol., 1961, 39, 787-827.http://dx.doi.org/10.1139/o61-081
91. [91][91] Tucek, S. Regulation of acetylcholine synthesis in the brain. J. Neurochem., 1985, 44, 11-24.http://dx.doi.org/10.1111/j.1471-4159.1985.tb07106.x
92. [92] Vickroy, T.W.; Roeske, W.R.; Gehlert, D.R.; Wamsley, J.K.; Yamamura, H.I. Quantitative light microscopic autoradiography of [3H]hemicholinium-3 binding sites in the rat central nervous system: a novel biochemical marker for mapping the distribution of cholinergic nerve terminals. Brain Res., 1985, 329, 368-373.http://dx.doi.org/10.1016/0006-8993(85)90553-0
93. [93][93] Misawa, H.; Nakata, K.; Matsuura, J., Kobayashi, Y., Okuda, T., Fujioka, Y., Matsumura, G., Nishimura, Y., Haga, T. Distribution of the high-affinity choline transporter in the central nervous system of the rat. Neuroscience, 2001, 105, 87-98.http://dx.doi.org/10.1016/S0306-4522(01)00147-6
94. [94][94] Kobayashi, Y.; Okuda, T.; Fujioka, Y., Haga, T. Distribution of the high-affinity choline transporter in the human and macaque monkey spinal cord. Neurosci. Lett., 2002, 317, 25-28.http://dx.doi.org/10.1016/S0304-3940(01)02413-2
95. [95][95] Haga, T. Synthesis and release of (14 C) acetylcholine in synaptosomes. J. Neurochem., 1971, 18, 781-798.http://dx.doi.org/10.1111/j.1471-4159.1971.tb12008.x
96. [96][96] Kuhar, M.J.; Murrin, L.C. Sodium-dependent, high affinity choline uptake. J. Neurochem., 1978, 30, 15-21.http://dx.doi.org/10.1111/j.1471-4159.1978.tb07029.x
97. [97][97] Ferguson, S.M.; Bazalakova, M., Savchenko, V., Tapia, J.C., Wright, J., Blakely, R.D. Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Proc. Natl. Acad. Sci. U.S.A, 2004, 101, 8762-8767.http://dx.doi.org/10.1073/pnas.0401667101
98. [98][98] Ferguson, S.M.; Savchenko, V.; Apparsundaram, S., Zwick, M., Wright, J., Heilman, C.J., Yi, H., Levey, A.I., Blakely, R.D. Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J. Neurosci., 2003, 23, 9697-9709.
99. [99][99] Ribeiro, F.M.; Alves-Silva, J.; Volknandt, W., Martins-Silva, C., Mahmud, H., Wilhelm, A., Gomez, M.V., Rylett, R.J., Ferguson, S.S., Prado, V.F., Prado, M.A. The hemicholinium-3 sensitive high affinity choline transporter is internalized by clathrin-mediated endocytosis and is present in endosomes and synaptic vesicles. J. Neurochem., 2003, 87, 136-146.http://dx.doi.org/10.1046/j.1471-4159.2003.01974.x
100. [100][100] Nakata, K.; Okuda, T.; Misawa, H. Ultrastructural localization of high-affinity choline transporter in the rat neuromuscular junction: enrichment on synaptic vesicles. Synapse, 2004, 53, 53-56.http://dx.doi.org/10.1002/syn.20029
101. [101][101] Ribeiro, F.M.; Black, S.A.; Cregan, S.P., Prado, V.F., Prado, M.A., Rylett, R.J., Ferguson, S.S. Constitutive high-affinity choline transporter endocytosis is determined by a carboxyl-terminal tail dileucine motif. J. Neurochem., 2005, 94, 86-96.http://dx.doi.org/10.1111/j.1471-4159.2005.03171.x
102. [102][102] Ribeiro, F.M.; Pinthong, M.; Black, S.A., Gordon, A.C., Prado, V.F., Prado, M.A., Rylett, R.J., Ferguson, S.S. Regulated recycling and plasma membrane recruitment of the high-affinity choline transporter. Eur. J. Neurosci., 2007, 26, 3437-3448.http://dx.doi.org/10.1111/j.1460-9568.2007.05967.x
103. [103][103] O'Regan, S.; Collier, B. Effect of increasing choline, in vivo and in vitro, on the synthesis of acetylcholine in a sympathetic ganglion. J. Neurochem., 1981, 36, 420-430.http://dx.doi.org/10.1111/j.1471-4159.1981.tb01610.x
104. [104] Saltarelli, M.D.; Lowenstein, P.R.; Coyle, J.T. Rapid in vitro modulation of [3H]hemicholinium-3 binding sites in rat striatal slices. Eur. J. Pharmacol., 1987, 135, 35-40.http://dx.doi.org/10.1016/0014-2999(87)90754-0
105. [105][105] Apparsundaram, S.; Martinez, V.; Parikh, V.; Kozak, R.; Sarter, M. Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. J. Neurosci., 2005, 25, 3851-3856.http://dx.doi.org/10.1523/JNEUROSCI.0205-05.2005
106. [106][106] Levey, A.I.; Armstrong, D.M.; Atweh, S.F.; Terry, R.D.; Wainer, B. h. Monoclonal antibodies to choline acetyltransferase: production, specificity, and immune histochemistry. J. Neurosci., 1983, 3, 1-9.
107. [107][107] Woolf, N.J.; Butcher, L.L. Cholinergic neurons in the caudateputamen complex proper are intrinsically organized: a combined Evans blue and acetylcholinesterase analysis. Brain Res. Bull., 1981, 7, 487-507.http://dx.doi.org/10.1016/0361-9230(81)90004-6
108. [108][108] Bolam, J.P.; Wainer, B. h.; Smith, A.D. Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience, 1984, 12, 711-718.http://dx.doi.org/10.1016/0306-4522(84)90165-9
109. [109][109] Mesulam, M.M.; Mufson, E.J.; Levey, A.I.; Wainer, B. h. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol., 1983, 214, 170-197.http://dx.doi.org/10.1002/cne.902140206
110. [110][110] Mesulam, M.M.; Mufson, E.J.; Wainer, B. h.; Levey, A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience, 1983, 10, 1185-1201.http://dx.doi.org/10.1016/0306-4522(83)90108-2
111. [111][111] Mesulam, M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res., 2004, 145, 67-78.http://dx.doi.org/10.1016/S0079-6123(03)45004-8
112. [112][112] Richardson, R.T.; DeLong, M.R. A reappraisal of the functions of the nucleus basalis of Meynert. Trends Neurosci., 1988, 11, 264-267.http://dx.doi.org/10.1016/0166-2236(88)90107-5
113. [113][113] Everitt, B.J.; Robbins, T.W. Central cholinergic systems and cognition. Annu. Rev. Psychol., 1997, 48, 649-684.http://dx.doi.org/10.1146/annurev.psych.48.1.649
114. [114][114] Weinberger, N.M. The nucleus basalis and memory codes: auditory cortical plasticity and the induction of specific, associative behavioral memory. Neurobiol. Learn. Mem., 2003, 80, 268-284.http://dx.doi.org/10.1016/S1074-7427(03)00072-8
115. [115][115] Jones, B.E. Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. Prog. Brain Res., 2004, 145, 157-169.http://dx.doi.org/10.1016/S0079-6123(03)45011-5
116. [116][116] Rye, D.B.; Saper, C.B.; Lee, H.J.; Wainer, B. h. Pedunculopontine tegmental nucleus of the rat: cytoarchitecture, cytochemistry, and some extrapyramidal connections of the mesopontine tegmentum. J. Comp. Neurol., 1987, 259, 483-528.http://dx.doi.org/10.1002/cne.902590403
117. [117][117] Hobson, J.A.; McCarley, R.W.; Wyzinski, P.W. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science, 1975, 189, 55-58.http://dx.doi.org/10.1126/science.1094539
118. [118][118] Toyoshima, C.; Unwin, N. Three-dimensional structure of the acetylcholine receptor by cryoelectron microscopy and helical image reconstruction. J. Cell Biol., 1990, 111, 2623-2635.http://dx.doi.org/10.1083/jcb.111.6.2623
119. [119][119] Brisson, A.; Unwin, P.N. Quaternary structure of the acetylcholine receptor. Nature, 1985, 315, 474-477.http://dx.doi.org/10.1038/315474a0
120. [120][120] Brisson, A.; Unwin, P.N. Tubular crystals of acetylcholine receptor. J. Cell Biol., 1984, 99, 1202-1211.http://dx.doi.org/10.1083/jcb.99.4.1202
121. [121][121] Cooper, E.; Couturier, S.; Ballivet, M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature, 1991, 350, 235-238.http://dx.doi.org/10.1038/350235a0
122. [122][122] Nai, Q.; McIntosh, J.M.; Margiotta, J.F. Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function. Mol. Pharmacol., 2003, 63, 311-324.http://dx.doi.org/10.1124/mol.63.2.311
123. [123][123] Seguela, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J.A.; Patrick, J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci., 1993, 13, 596-604.
124. [124][124] Fenster, C.P.; Rains, M.F.; Noerager, B.; Quick, M.W.; Lester, R.A. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J. Neurosci., 1997, 17, 5747-5759.
125. [125][125] Role, L.W.; Berg, D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron, 1996, 16, 1077-1085.http://dx.doi.org/10.1016/S0896-6273(00)80134-8
126. [126][126] Whyte, J.; Harrison, R.; Lunt, G.G.; Wonnacott, S. Subcellular fractionation and distribution of cholinergic binding sites in fetal human brain. Neurochem. Res., 1986, 11, 1011-1023.http://dx.doi.org/10.1007/BF00965590
127. [127][127] Radcliffe, K.A.; Dani, J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J. Neurosci., 1998, 18, 7075-7083.
128. [128][128] Gray, R.; Rajan, A.S.; Radcliffe, K.A.; Yakehiro, M.; Dani, J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature, 1996, 383, 713-716.http://dx.doi.org/10.1038/383713a0
129. [129][129] Radcliffe, K.A.; Fisher, J.L.; Gray, R.; Dani, J.A. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann. N. Y. Acad. Sci., 1999, 868, 591-610.
130. [130][130] McGehee, D.S.; Heath, M.J.; Gelber, S.; Devay, P.; Role, L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science, 1995, 269, 1692-1696.http://dx.doi.org/10.1126/science.7569895
131. [131][131] Wilkie, G.I.; Hutson, P.; Sullivan, J.P.; Wonnacott, S. Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. Neurochem. Res., 1996, 21, 1141-1148.http://dx.doi.org/10.1007/BF02532425
132. [132] Clarke, P.B.; Reuben, M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br. J. Pharmacol., 1996, 117, 595-606.http://dx.doi.org/10.1111/j.1476-5381.1996.tb15232.x
133. [133][133] Nisell, M.; Nomikos, G.G.; Svensson, T. h. Systemic nicotineinduced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse, 1994, 16, 36-44.http://dx.doi.org/10.1002/syn.890160105
134. [134][134] Yang, X.; Criswell, H.E.; Breese, G.R. Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-containing neurons. J. Pharmacol. Exp. Ther., 1996, 276, 482-489.
135. [135][135] Wessler, I. Acetylcholine at motor nerves: storage, release, and presynaptic modulation by autoreceptors and adrenoceptors. Int. Rev. Neurobiol., 1992, 34, 283-384.http://dx.doi.org/10.1016/S0074-7742(08)60100-2
136. [136][136] Wonnacott, S. Presynaptic nicotinic ACh receptors. Trends Neurosci., 1997, 20, 92-98.http://dx.doi.org/10.1016/S0166-2236(96)10073-4
137. [137][137] Kim, J.S.; Levin, E.D. Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. Brain Res., 1996, 725, 231-240.http://dx.doi.org/10.1016/0006-8993(96)00213-2
138. [138][138] Levin, E.D.; Simon, B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl), 1998, 138, 217-230.http://dx.doi.org/10.1007/s002130050667
139. [139][139] Levin, E.D.; Torry, D. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology (Berl), 1996, 123, 88-97.http://dx.doi.org/10.1007/BF02246285
140. [140][140] Felix, R.; Levin, E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience, 1997, 81, 1009-1017.http://dx.doi.org/10.1016/S0306-4522(97)00224-8
141. [141][141] Dajas-Bailador, F.A.; Lima, P.A.; Wonnacott, S. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology, 2000, 39, 2799-2807.http://dx.doi.org/10.1016/S0028-3908(00)00127-1
142. [142][142] O'Neill, M.J.; Murray, T.K.; Lakics, V.; Visanji, N.P.; Duty, S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets. CNS. Neurol. Disord., 2002, 1, 399-411.http://dx.doi.org/10.2174/1568007023339166
143. [143][143] Hsu, Y.N.; Edwards, S.C.; Wecker, L. Nicotine enhances the cyclic AMP-dependent protein kinase-mediated phosphorylation of alpha4 subunits of neuronal nicotinic receptors. J. Neurochem., 1997, 69, 2427-2431.http://dx.doi.org/10.1046/j.1471-4159.1997.69062427.x
144. [144][144] Cho, C. h.; Song, W.; Leitzell, K., Teo, E., Meleth, A.D., Quick, M.W., Lester, R.A. Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J. Neurosci., 2005, 25, 3712-3723.http://dx.doi.org/10.1523/JNEUROSCI.5389-03.2005
145. [145][145] Swope, S.L.; Moss, S.J.; Raymond, L.A.; Huganir, R.L. Regulation of ligand-gated ion channels by protein phosphorylation. Adv. Second Messenger Phosphoprotein Res., 1999, 33, 49-78.http://dx.doi.org/10.1016/S1040-7952(99)80005-6
146. [146][146] Charpantier, E.; Wiesner, A.; Huh, K. h., Ogier, R., Hoda, J.C., Allaman, G., Raggenbass, M., Feuerbach, D., Bertrand, D. Fuhrer C. Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J. Neurosci., 2005, 25, 9836-9849.http://dx.doi.org/10.1523/JNEUROSCI.3497-05.2005
147. [147][147] Mulle, C.; Lena, C.; Changeux, J.P. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron, 1992, 8, 937-945.http://dx.doi.org/10.1016/0896-6273(92)90208-U
148. [148][148] Glushakov, A.V.; Glushakova, H.Y.; Skok, V.I. Modulation of nicotinic acetylcholine receptor activity in submucous neurons by intracellular messengers. J. Auton. Nerv. Syst., 1999, 75, 16-22.http://dx.doi.org/10.1016/S0165-1838(98)00165-9
149. [149][149] Luetje, C.W.; Patrick, J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci., 1991, 11, 837-845.
150. [150][150] Chavez-Noriega, L.E.; Crona, J. h.; Washburn, M.S., Urrutia, A., Elliott, K.J., Johnson, E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther., 1997, 280, 346-356.
151. [151][151] Mogg, A.J.; Whiteaker, P.; McIntosh, J.M., et al. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MIIsensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J. Pharmacol. Exp. Ther., 2002, 302, 197-204.http://dx.doi.org/10.1124/jpet.302.1.197
152. [152][152] Nathanson, N.M. A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away. Proc. Natl. Acad. Sci. U.S.A, 2000, 97, 6245-6247.http://dx.doi.org/10.1073/pnas.97.12.6245
153. [153][153] Bonner, T.I.; Buckley, N.J.; Young, A.C.; Brann, M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science, 1987, 237, 527-532.http://dx.doi.org/10.1126/science.3037705
154. [154][154] Kubo, T.; Maeda, A.; Sugimoto, K., Akiba, I., Mikami, A., Takahashi, H., Haga, T., Haga, K., Ichiyama, A., Kangawa, K., et al. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett., 1986, 209, 367-372.http://dx.doi.org/10.1016/0014-5793(86)81144-9
155. [155][155] Caulfield, M.P.; Birdsall, N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 1998, 50, 279-290.
156. [156][156] Hammer, R.; Berrie, C.P.; Birdsall, N.J.; Burgen, A.S.; Hulme, E.C. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature, 1980, 283, 90-92.http://dx.doi.org/10.1038/283090a0
157. [157][157] Ehlert, F.J.; Delen, F.M.; Yun, S. h.; Tran, P. Differential coupling of subtypes of the muscarinic receptor to signaling mechanisms in brain and peripheral tissues. Adv. Exp. Med. Biol., 1991, 287, 301-312.http://dx.doi.org/10.1007/978-1-4684-5907-4_25
158. [158][158] Egan, T.M.; North, R.A. Acetylcholine hyperpolarizes central neurones by acting on an M2 muscarinic receptor. Nature, 1986, 319, 405-407.http://dx.doi.org/10.1038/319405a0
159. [159][159] Felder, C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J., 1995, 9, 619-625.
160. [160][160] Krnjevic, K.; Pumain, R.; Renaud, L. The mechanism of excitation by acetylcholine in the cerebral cortex. J. Physiol., 1971, 215, 247-268.http://dx.doi.org/10.1113/jphysiol.1971.sp009467
161. [161][161] Brown, D.A.; Selyanko, A.A. Membrane currents underlying the cholinergic slow excitatory post-synaptic potential in the rat sympathetic ganglion. J. Physiol., 1985, 365, 365-387.
162. [162][162] Kudo, Y.; Ogura, A.; Iijima, T. Stimulation of muscarinic receptor in hippocampal neuron induces characteristic increase in cytosolic free Ca2+ concentration. Neurosci. Lett., 1988, 85, 345-350.http://dx.doi.org/10.1016/0304-3940(88)90590-3
163. [163][163] Levey, A.I.; Kitt, C.A.; Simonds, W.F.; Price, D.L.; Brann, M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci., 1991, 11, 3218-3226.
164. [164][164] Mrzljak, L.; Levey, A.I.; Goldman-Rakic, P.S. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc. Natl. Acad. Sci. U.S.A, 1993, 90, 5194-5198.http://dx.doi.org/10.1073/pnas.90.11.5194
165. [165][165] Porter, A.C.; Bymaster, F.P.; DeLapp, N.W., Yamada, M., Wess, J., Hamilton, S.E., Nathanson, N.M., Felder, C.C. M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res., 2002, 944, 82-89.http://dx.doi.org/10.1016/S0006-8993(02)02721-X
166. [166][166] Douglas, C.L.; Baghdoyan, H.A.; Lydic, R. M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL/6J mouse. J. Pharmacol. Exp. Ther., 2001, 299, 960-966.
167. [167][167] Segal, M. Presynaptic cholinergic inhibition in hippocampal cultures. Synapse, 1989, 4, 305-312.http://dx.doi.org/10.1002/syn.890040406
168. [168][168] Van der Zee, E.A.; Luiten, P.G. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog. Neurobiol., 1999, 58, 409-471.http://dx.doi.org/10.1016/S0301-0082(98)00092-6
169. [169][169] Halliwell, J.V.; Adams, P.R. Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res., 1982, 250, 71-92.http://dx.doi.org/10.1016/0006-8993(82)90954-4
170. [170][170] Nakajima, Y.; Nakajima, S.; Leonard, R.J.; Yamaguchi, K. Acetylcholine raises excitability by inhibiting the fast transient potassium current in cultured hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A, 1986, 83, 3022-3026.http://dx.doi.org/10.1073/pnas.83.9.3022
171. [171][171] Madison, D.V.; Lancaster, B.; Nicoll, R.A. Voltage clamp analysis of cholinergic action in the hippocampus. J. Neurosci., 1987, 7, 733-741.
172. [172][172] Hounsgaard, J. Presynaptic inhibitory action of acetylcholine in area CA1 of the hippocampus. Exp. Neurol., 1978, 62, 787-797.http://dx.doi.org/10.1016/0014-4886(78)90284-4
173. [173][173] Segal, M. Rat hippocampal neurons in culture: responses to electrical and chemical stimuli. J. Neurophysiol., 1983, 50, 1249-1264.
174. [174][174] Markram, H.; Segal, M. The inositol 1, 4, 5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. J. Physiol., 1992, 447, 513-533.http://dx.doi.org/10.1113/jphysiol.1992.sp019015
175. [175][175] McCormick, D.A.; Prince, D.A. Mechanisms of action of acetylcholine in the guinea-pig cerebral cortex in vitro. J. Physiol., 1986, 375, 169-194.http://dx.doi.org/10.1113/jphysiol.1986.sp016112
176. [176][176] Rovira, C.; Ben Ari, Y.; Cherubini, E.; Krnjevic, K.; Ropert, N. Pharmacology of the dendritic action of acetylcholine and further observations on the somatic disinhibition in the rat hippocampus in situ. Neuroscience, 1983, 8, 97-106.http://dx.doi.org/10.1016/0306-4522(83)90028-
177. [177][177] Gahwiler, B. h.; Brown, D.A. Muscarine affects calcium-currents in rat hippocampal pyramidal cells in vitro. Neurosci. Lett., 1987, 76, 301-306.http://dx.doi.org/10.1016/0304-3940(87)90419-8
178. [178][178] Adem, A.; Karlsson, E. Muscarinic receptor subtype selective toxins. Life Sci., 1997, 60, 1069-1076.http://dx.doi.org/10.1016/S0024-3205(97)00049-0
179. [179][179] Wilcock, G.K.; Esiri, M.M.; Bowen, D.M.; Smith, C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci., 1982, 57, 407-417.http://dx.doi.org/10.1016/0022-510X(82)90045-4
180. [180][180] Muir, J.L. Acetylcholine, aging, and Alzheimer's disease. Pharmacol. Biochem. Behav., 1997, 56, 687-696.http://dx.doi.org/10.1016/S0091-3057(96)00431-5
181. [181] Bartus, R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol., 2000, 163, 495-529.http://dx.doi.org/10.1006/exnr.2000.7397
182. [182][182] Muir, J.L.; Dunnett, S.B.; Robbins, T.W.; Everitt, B.J. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp. Brain Res., 1992, 89, 611-622.http://dx.doi.org/10.1007/BF00229886
183. [183][183] Rogers, J.L.; Kesner, R.P. Cholinergic modulation of the hippocampus during encoding and retrieval of tone/shock-induced fear conditioning. Learn Mem., 2004, 11, 102-107.http://dx.doi.org/10.1101/lm.64604
184. [184][184] Rosenberg, P.B.; Nowrangi, M.A.; Lyketsos, C.G. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? Mol. Aspects Med., 2015.http://dx.doi.org/10.1016/j.mam.2015.05.005
185. [185][185] Martorana, A.; Koch, G. “Is dopamine involved in Alzheimer's disease?”Front Aging Neurosci., 2014, 6, 252.http://dx.doi.org/10.3389/fnagi.2014.00252
186. [186][186] Jeon, J.; Dencker, D.; Wortwein, G., Woldbye, D.P., Cui, Y., Davis, A.A., Levey, A.I., Schutz, G., Sager, T.N., Mork, A., Li, C., Deng, C.X., Fink-Jensen, A., Wess, J. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J. Neurosci., 2010, 30, 2396-2405.http://dx.doi.org/10.1523/JNEUROSCI.3843-09.2010
187. [187][187] Mesulam, M.M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J. Comp. Neurol., 2013, 521, 4124-4144.http://dx.doi.org/10.1002/cne.23415
188. [188][188] Sarter, M.; Lustig, C.; Howe, W.M.; Gritton, H.; Berry, A.S. Deterministic functions of cortical acetylcholine. Eur. J. Neurosci., 2014, 39, 1912-1920.http://dx.doi.org/10.1111/ejn.12515
189. [189][189] Nauta, W.J.; Smith, G.P.; Faull, R.L.; Domesick, V.B. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience, 1978, 3, 385-401.http://dx.doi.org/10.1016/0306-4522(78)90041-6
190. [190][190] Arendt, T.; Bigl, V.; Arendt, A.; Tennstedt, A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol., 1983, 61, 101-108.http://dx.doi.org/10.1007/BF00697388
191. [191][191] Dubois, B.; Ruberg, M.; Javoy-Agid, F.; Ploska, A.; Agid, Y. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res., 1983, 288, 213-218.http://dx.doi.org/10.1016/0006-8993(83)90096-3
192. [192][192] Yates, C.M.; Simpson, J.; Maloney, A.F.; Gordon, A.; Reid, A. h. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet, 1980, 2, 979.http://dx.doi.org/10.1016/S0140-6736(80)92137-6
193. [193][193] Barron, S.A.; Mazliah, J.; Bental, E. Sympathetic cholinergic dysfunction in amyotrophic lateral sclerosis. Acta Neurol. Scand., 1987, 75, 62-63.http://dx.doi.org/10.1111/j.1600-0404.1987.tb07890.x
194. [194][194] Kato, T. Choline acetyltransferase activities in single spinal motor neurons from patients with amyotrophic lateral sclerosis. J. Neurochem., 1989, 52, 636-640.http://dx.doi.org/10.1111/j.1471-4159.1989.tb09167.x
195. [195][195] Ruberg, M.; Javoy-Agid, F.; Hirsch, E., Scatton, B L., Heureux, R., Hauw, J.J., Duyckaerts, C., Gray, F., Morel-Maroger, A., Rascol, A. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann. Neurol., 1985, 18, 523-529.http://dx.doi.org/10.1002/ana.410180503
196. [196][196] Tagliavini, F.; Pilleri, G.; Bouras, C.; Constantinidis, J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci. Lett., 1984, 44, 37-42.http://dx.doi.org/10.1016/0304-3940(84)90217-9
197. [197][197] Kish, S.J.; el Awar, M.; Schut, L., Leach, L., Oscar-Berman, M., Freedman, M. Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer's dementia. Ann. Neurol., 1988, 24, 200-206.http://dx.doi.org/10.1002/ana.410240205
198. [198][198] Ferrante, R.J.; Beal, M.F.; Kowall, N.W.; Richardson, E.P., Jr.; Martin, J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res., 1987, 411, 162-166.http://dx.doi.org/10.1136/jnnp.38.7.669
199. [199][199] Aquilonius, S.M.; Eckernas, S.A.; Sundwall, A. Regional distribution of choline acetyltransferase in the human brain: changes in Huntington's chorea. J. Neurol. Neurosurg. Psychiatry, 1975, 38, 669-677.http://dx.doi.org/10.1136/jnnp.38.7.669
200. [200][200] Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin., 1907, 64, 146-148.
201. [201][201] Ferri, C.P.; Prince, M.; Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y, Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366, 2112-2117.http://dx.doi.org/10.1016/S0140-6736(05)67889-0
202. [202][202] Plassman, B.L.; Langa, K.M.; Fisher, G.G., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology, 2007, 29, 125-132.http://dx.doi.org/10.1159/000109998
203. [203][203] Waldemar, G.; Dubois, B.; Emre, M., Georges, J., McKeith, I.G., Rossor, M., Scheltens, P., Tariska, P., Winblad, B.; EFNS. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol., 2007, 14, 1-26.http://dx.doi.org/10.1111/j.1468-1331.2006.01605.x
204. [204][204] Qiu, C.; Kivipelto, M.; von Strauss, E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialog. Clin. Neurosci., 2009, 11, 111-128.
205. [205][205] De-Paula, V.J.; Radanovic, M.; Diniz, B.S.; Forlenza, O.V. Alzheimer's disease. Subcell. Biochem., 2012, 65, 329-352.http://dx.doi.org/10.1007/978-94-007-5416-4_14
206. [206][206] Armstrong, R.A. Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression. Biomed. Res. Int., 2014, 2014, 623-487.
207. [207] Garin, D.; Virgone-Carlotta, A.; Gozel, B., Oukhatar, F., Perret, P., Marti-Battle, D., Touret, M., Millet, P., Dubois-Dauphin, M., Meyronet, D., Streichenberger, N., Laferla, F.M., Demeunynck, M., Chierici, S., Sallanon, M.M., Ghezzi, C. COB231 targets amyloid plaques in post-mortem human brain tissue and in an Alzheimer mouse model. J. Neurochem., 2014, [Epub a head of Print].
208. [208][208] Duyckaerts, C.; Delatour, B.; Potier, M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol., 2009, 118, 5-36.http://dx.doi.org/10.1007/s00401-009-0532-1
209. [209][209] Taipa, R.; Pinho, J.; Melo-Pires, M. Clinico-pathological correlations of the most common neurodegenerative dementias. Front. Neurol., 2012, 3, 68.http://dx.doi.org/10.3389/fneur.2012.00068
210. [210][210] Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 1984, 120, 885-890.http://dx.doi.org/10.1016/S0006-291X(84)80190-4
211. [211][211] Kang, J.; Lemaire, H.G.; Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K., Muller-Hill, B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987, 325, 733-736.http://dx.doi.org/10.1038/325733a0
212. [212][212] Esch, F.S.; Keim, P.S.; Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., Ward, P.J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science, 1990, 248, 1122-1124.http://dx.doi.org/10.1126/science.2111583
213. [213][213] Terry, R.D.; Masliah, E.; Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30, 572-580.http://dx.doi.org/10.1002/ana.410300410
214. [214][214] Terry, R.D. Alzheimer's disease and the aging brain. J. Geriatr. Psychiatry Neurol., 2006, 19, 125-128.http://dx.doi.org/10.1177/0891988706291079
215. [215][215] Kosik, K.S.; Joachim, C.L.; Selkoe, D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A, 1986, 83, 4044-4048.http://dx.doi.org/10.1073/pnas.83.11.4044
216. [216][216] Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. U.S.A, 1986, 83, 4040-4043.http://dx.doi.org/10.1073/pnas.83.11.4040
217. [217][217] Berg, L.; McKeel, D.W., Jr.; Miller, J.P.; Baty, J.; Morris, J.C. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol., 1993, 50, 349-358.http://dx.doi.org/10.1001/archneur.1993.00540040011008
218. [218][218] Wong, T.P.; Debeir, T.; Duff, K.; Cuello, A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci., 1999, 19, 2706-2716.
219. [219][219] Bell, K.F.; Ducatenzeiler, A.; Ribeiro-da-Silva, A.; Duff, K.; Bennett, D.A.; Cuello, A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging, 2006, 27, 1644-1657.http://dx.doi.org/10.1016/j.neurobiolaging.2005.09.034
220. [220][220] Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298, 789-791.http://dx.doi.org/10.1126/science.1074069
221. [221][221] Sze, C.I.; Troncoso, J.C.; Kawas, C., Mouton, P., Price, D.L., Martin, L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol., 1997, 56, 933-944.http://dx.doi.org/10.1097/00005072-199708000-00011
222. [222][222] Counts, S.E.; Nadeem, M.; Lad, S.P.; Wuu, J.; Mufson, E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol., 2006, 65, 592-601.http://dx.doi.org/10.1097/00005072-200606000-00007
223. [223][223] Hsia, A.Y.; Masliah, E.; McConlogue, L., McConlogue, L., Yu, G.Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R.C., Nicoll, R.A., Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 3228-3233.http://dx.doi.org/10.1073/pnas.96.6.3228
224. [224][224] Fitzjohn, S.M.; Morton, R.A.; Kuenzi, F., Rosahl, T.W., Shearman, M., Lewis, H., Smith, D., Reynolds, D.S., Davies, C.H., Collingridge, G.L., Seabrook, G.R. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci., 2001, 21, 4691-4698.
225. [225][225] Schliebs, R.; Arendt, T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural. Transm., 2006, 113, 1625-1644.http://dx.doi.org/10.1007/s00702-006-0579-2
226. [226][226] Bowen, D.M.; Smith, C.B.; White, P.; Davison, A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 1976, 99, 459-496.http://dx.doi.org/10.1093/brain/99.3.459
227. [227][227] Strada, O.; Vyas, S.; Hirsch, E.C., Ruberg, M., Brice, A., Agid, Y., Javoy-Agid, F. Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 9549-9553.http://dx.doi.org/10.1073/pnas.89.20.9549
228. [228][228] Oda, Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol.Int., 1999, 49, 921-937.http://dx.doi.org/10.1046/j.1440-1827.1999.00977.x
229. [229][229] Mesulam, M.M. Alzheimer plaques and cortical cholinergic innervation. Neuroscience, 1986, 17, 275-276.http://dx.doi.org/10.1016/0306-4522(86)90242-3
230. [230][230] Lahiri, D.K.; Utsuki, T.; Chen, D., Farlow, M.R., Shoaib, M., Ingram, D.K., Greig, N.H. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing betaamyloid peptide in the rat without altering synaptic proteins. Ann. N. Y. Acad. Sci., 2002, 965, 364-372.http://dx.doi.org/10.1111/j.1749-6632.2002.tb04178.x
231. [231][231] Racchi, M.; Sironi, M.; Caprera, A.; Konig, G.; Govoni, S. Shortand long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol. Psychiatry, 2001, 6, 520-528.http://dx.doi.org/10.1038/sj.mp.4000878
232. [232][232] De Ferrari, G.V.; Canales, M.A.; Shin, I., Weiner, L.M., Silman, I., Inestrosa, N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 2001, 40, 10447-10457.http://dx.doi.org/10.1021/bi0101392
233. [233][233] Apelt, J.; Kumar, A.; Schliebs, R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res., 2002, 953, 17-30.http://dx.doi.org/10.1016/S0006-8993(02)03262-6
234. [234][234] Raina, P.; Santaguida, P.; Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., Oremus, M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med., 2008, 148, 379-397.http://dx.doi.org/10.7326/0003-4819-148-5-200803040-00009
235. [235][235] Sun, Y.; Lai, M.S.; Lu, C.J.; Chen, R.C. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur. J. Neurol., 2008, 15, 278-283.http://dx.doi.org/10.1111/j.1468-1331.2007.02049.x
236. [236][236] Howard, R.; McShane, R.; Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., Phillips, P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med., 2012, 366, 893-903.http://dx.doi.org/10.1056/NEJMoa1106668
237. [237][237] Hager, K.; Baseman, A.S.; Nye, J.S., Brashear, H.R., Han, J., Sano, M., Davis, B., Richards, H.M. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr. Dis. Treat., 2014, 10, 391-401.
238. [238][238] Dhillon, S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs, 2011, 71, 1209-1231.http://dx.doi.org/10.2165/11206380-000000000-00000
239. [239][239] Guay, D.R. Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult. Pharm., 2008, 23, 598-609.http://dx.doi.org/10.4140/TCP.n.2008.598
240. [240][240] Galimberti, D.; Ghezzi, L.; Scarpini, E. Immunotherapy against amyloid pathology in Alzheimer's disease. J. Neurol. Sci., 2013, 333, 50-54.http://dx.doi.org/10.1016/j.jns.2012.12.013
241. [241][241] Giacobini, E.; Becker, R.E. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J. AlzheimersDis., 2007, 12, 37-52.
242. [242][242] Tsang, S.W.; Lai, M.K.; Kirvell, S., Francis, P.T., Esiri, M.M., Hope, T., Chen, C.P., Wong, P.T..Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging, 2006, 27, 1216-1223.http://dx.doi.org/10.1016/j.neurobiolaging.2005.07.010
243. [243][243] Buxbaum, J.D.; Oishi, M.; Chen, H.I., Pinkas-Kramarski, R., Jaffe, E.A., Gandy, S.E., Greengard, P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 10075-10078.http://dx.doi.org/10.1073/pnas.89.21.10075
244. [244][244] Nitsch, R.M.; Slack, B.E.; Wurtman, R.J.; Growdon, J. h. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science, 1992, 258, 304-307.http://dx.doi.org/10.1126/science.1411529
245. [245][245] Fisher, A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors. Neurodegener Dis, 2008, 5, 237-240.http://dx.doi.org/10.1159/000113712
246. [246][246] Fisher, A.; Brandeis, R.; Bar-Ner, R. h., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., Pittel, Z.A.F. 150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J. Mol. Neurosci., 2002, 19, 145-153.http://dx.doi.org/10.1007/s12031-002-0025-3
247. [247][247] Caccamo, A.; Oddo, S.; Billings, L.M.; Green, K.N.; Martinez- Coria, H.; Fisher, A.; LaFerla, F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron, 2006, 49, 671-682.http://dx.doi.org/10.1016/j.neuron.2006.01.020
248. [248][248] Forlenza, O.V.; Spink, J.M.; Dayanandan, R., Anderton, B.H., Olesen, O.F., Lovestone, S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural. Transm., 2000, 107, 1201-1212.http://dx.doi.org/10.1007/s007020070034
249. [249][249] Jones, C.K.; Brady, A.E.; Davis, A.A., Xiang, Z., Bubser, M., Tantawy, M.N., Kane, A.S., Bridges, T.M., Kennedy, J.P., Bradley, S.R., Peterson, T.E., Ansari, M.S., Baldwin, R.M., Kessler, R.M., Deutch, A.Y., Lah, J.J., Levey, A.I., Lindsley, C.W., Conn, P. J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci., 2008, 28, 10422-10433.http://dx.doi.org/10.1523/JNEUROSCI.1850-08.2008
250. [250][250] Boyle, C.D.; Lachowicz, J.E. Orally active and selective benzylidene Ketal M-2 muscarinic receptor antagonists for the treatment of Alzheimer's disease. Drug Develop. Res., 2002, 56, 310-320.http://dx.doi.org/10.1002/ddr.10084
251. [251][251] Zuchner, T.; Perez-Polo, J.R.; Schliebs, R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J. Neurosci. Res., 2004, 77, 250-257.http://dx.doi.org/10.1002/jnr.20152
252. [252][252] Dineley, K.T. Beta-amyloid peptide--nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front. Biosci., 2007, 12, 5030-5038.http://dx.doi.org/10.2741/2445
253. [253][253] Bodick, N.C.; Offen, W.W.; Levey, A.I., Cutler, N.R., Gauthier, S. G., Satlin, A., Shannon, H.E., Tollefson, G.D., Rasmussen, K., Bymaster, F.P., Hurley, D.J., Potter, W.Z., Paul, S.M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol., 1997, 54, 465-473.http://dx.doi.org/10.1001/archneur.1997.00550160091022
254. [254][254] Shirey, J.K.; Brady, A.E.; Jones, P.J., Davis, A.A., Bridges, T.M., Kennedy, J.P., Jadhav, S.B., Menon, U.N., Xiang, Z., Watson, M.L., Christian, E.P., Doherty, J.J., Quirk, M.C., Snyder, D.H., Lah, J.J., Levey, A.I., Nicolle, M.M., Lindsley, C.W., Conn, P.J.A. selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci., 2009, 29, 14271-14286.http://dx.doi.org/10.1523/JNEUROSCI.3930-09.2009
255. [255][255] Conn, P.J.; Jones, C.K.; Lindsley, C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci., 2009, 30, 148-155.http://dx.doi.org/10.1016/j.tips.2008.12.002
256. [256][256] Shirey, J.K.; Xiang, Z.; Orton, D., Brady, A.E., Johnson, K.A., Williams R, Ayala, J.E., Rodriguez, A.L., Wess, J., Weaver, D., Niswender, C.M., Conn, P.J. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol., 2008, 4, 42-50.http://dx.doi.org/10.1038/nchembio.2007.55
257. [257][257] Brady, A.E.; Jones, C.K.; Bridges, T.M., Kennedy, J.P., Thompson, A.D., Heiman, J.U., Breininger, M.L., Gentry, P.R., Yin, H., Jadhav, S.B., Shirey, J.K., Conn, P.J., Lindsley, C. W.. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther., 2008, 327, 941-953.http://dx.doi.org/10.1124/jpet.108.140350
258. [258][258] Wang, B.; Yang, L.; Wang, Z.; Zheng, H. Amyolid precursor protein mediates presynaptic localization and activity of the highaffinity choline transporter. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 14140-14145.http://dx.doi.org/10.1073/pnas.0704070104
259. [259][259] Rogawski, M.A.; Wenk, G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev., 2003, 9, 275-308.http://dx.doi.org/10.1111/j.1527-3458.2003.tb00254.x
260. [260][260] Wenk, G.L.; Parsons, C.G.; Danysz, W. Potential role of N-methyl- D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav. Pharmacol., 2006, 17, 411-424.http://dx.doi.org/10.1097/00008877-200609000-00007
261. [261][261] Ong, W.Y.; Tanaka, K.; Dawe, G.S.; Ittner, L.M.; Farooqui, A.A. Slow excitotoxicity in Alzheimer's disease. J. Alzheimers Dis., 2013, 35, 643-668.
262. [262][262] Seiger, A.; Nordberg, A.; von Holst, H., Backman, L., Ebendal, T., Alafuzoff, I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav. Brain Res., 1993, 57, 255-261.http://dx.doi.org/10.1016/0166-4328(93)90141-C
263. [263][263] Eriksdotter, J.M.; Nordberg, A.; Amberla, K., Backman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, S.M., Theodorsson, E., Viitanen, M., Winblad, B., Wahlund, L.O. Intra cerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 1998, 9, 246-257.http://dx.doi.org/10.1159/000017069
264. [264][264] Tuszynski, M. h.; Thal, L.; Pay, M., Salmon, D.P. U. H.S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G., Tong, G., Potkin, S.G., Fallon, J., Hansen, L., Mufson, E.J., Kordower, J.H., Gall, C., Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11, 551-555.http://dx.doi.org/10.1038/nm1239
265. [265][265] Fischer, W.; Wictorin, K.; Bjorklund, A., Williams, L.R., Varon, S., Gage, F.H. melioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature, 1987, 329, 65-68.http://dx.doi.org/10.1038/329065a0
266. [266][266] Geylis, V.; Steinitz, M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun. Rev., 2006, 5, 33-39.http://dx.doi.org/10.1016/j.autrev.2005.06.007
267. [267][267] Janus, C.; Pearson, J.; McLaurin, J., Mathews, P.M., Jiang, Y., Schmidt, S.D., Chishti, M.A., Horne, P., Heslin, D., French, J., Mount, H.T., Nixon, R.A., Mercken, M., Bergeron, C., Fraser, P.E., St George-Hyslop, P., Westaway, D.A. Beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-982.http://dx.doi.org/10.1038/35050110
268. [268][268] Morgan, D.; Diamond, D.M.; Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.http://dx.doi.org/10.1038/35050116
269. [269][269] Schenk, D.; Barbour, R.; Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.http://dx.doi.org/10.1038/22124
270. [270][270] Bales, K.R.; Tzavara, E.T.; Wu, S., Wade, M.R., Bymaster, F.P., Paul, S.M., Nomikos, G. G. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J. Clin. Invest., 2006, 116, 825-832.http://dx.doi.org/10.1172/JCI27120
271. [271][271] Gilman, S.; Koller, M.; Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562.http://dx.doi.org/10.1212/01.WNL.0000159740.16984.3C
272. [272][272] Farlow, M.; Arnold, S.E.; van Dyck, C. h., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., DeMattos, R.B., Mohs, R., Paul, S.M., Siemers, E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement, 2012, 8, 261-271.http://dx.doi.org/10.1016/j.jalz.2011.09.224
273. [273][273] Nicoll, J.A.; Barton, E.; Boche, D., Neal, J.W., Ferrer, I., Thompson, P., Vlachouli, C, Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D., Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65, 1040-1048.http://dx.doi.org/10.1097/01.jnen.0000240466.10758.ce